Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Nuvectis Pharma (NVCT – Research Report). The associated price target is $11.00.
Joseph Pantginis has given his Buy rating due to a combination of factors, primarily focusing on the promising developments in Nuvectis Pharma’s oncology pipeline. The company’s ongoing clinical trials, particularly the NXP800 and NXP900 programs, show significant potential in treating challenging cancer types such as platinum-resistant, ARID1a-mutated ovarian cancer and YES1/SRC-driven solid tumors.
The interim data from the NXP800 Phase 1b trial is particularly encouraging, with improved safety outcomes and observable antitumor activity, including one unconfirmed partial response and several cases of stable disease. Additionally, Nuvectis’s financial position is strengthened by a recent cash raise, providing a runway into 2027, which supports continued development of their clinical programs. These factors collectively underpin Pantginis’s optimism about the company’s future prospects and justify the Buy rating.
Pantginis covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Cytokinetics, and Esperion. According to TipRanks, Pantginis has an average return of -5.2% and a 29.38% success rate on recommended stocks.